Anemia Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa versus placebo in AIDS patients for the treatment of anemia that is a result of the disease or a result of zidovudine (AZT) treatment for AIDS. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.
It is estimated that approximately 75% to 80% of patients with AIDS experience anemia, which
can be caused by AIDS or by the therapy patients receive for AIDS treatment (for example,
zidovudine [AZT]). Anemia is a condition in which a patient has below normal levels of
hemoglobin, the substance in red blood cells that carries oxygen to all parts of the body.
People with severe anemia may experience fatigue and shortness of breath with activity.
Therefore, this condition can have a negative influence on a person's quality of life.
Epoetin alfa, used to treat anemia, is a genetically engineered form of a natural hormone,
erythropoietin, that stimulates red blood cell production. This is a randomized,
double-blind, placebo-controlled study with an open-label follow-up period that is designed
to evaluate the safety and effectiveness of epoetin alfa treatment compared with placebo
treatment in patients with AIDS who are being treated with AZT. The study consists of three
periods: a screening period to determine if patients are eligible for the study, a
double-blind period, and an open-label period. During the double-blind period, patients are
randomly assigned to one of two groups and receive either epoetin alfa (100 units per
kilogram) or placebo injected into a vein (intravenously) three times per week for 12 weeks
or until their hematocrit reaches 38% to 40%. In the open-label period, all patients receive
epoetin alfa injected under the skin (subcutaneously) for up to 6 months at the dose needed
to maintain hematocrit levels of 38% to 40%. Effectiveness will be determined by the change
in hemoglobin, hematocrit, and reticulocyte count (laboratory tests used to evaluate the
severity of anemia), transfusion requirements, and the patient's quality of life assessment.
Safety assessments include the incidence and severity of adverse events during the study,
results of clinical laboratory tests (hematology, biochemistry, and urinalysis),
measurements of vital signs, electrocardiograms (ECGs) and physical examination findings.
The study hypothesis is that for treatment of anemia in patients with AIDS who are receiving
AZT therapy, epoetin alfa is superior to placebo, as measured by changes in hemoglobin,
hematocrit, and reticulocyte count, transfusion requirements, and the patient's quality of
life.
Double-blind period: epoetin alfa (100 units per kilogram [U/kg] of body weight) or placebo,
injected intravenously three times a week for 12 weeks. Open-label period: epoetin alfa
injected under the skin for up to 6 months, with dose adjustments in the range of 0 to 1,500
U/kg as needed to maintain hematocrit levels of 38% to 40%.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A |